27965933|t|Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome
27965933|a|Personalized therapy of colorectal cancer is influenced by morphological, molecular, and host-related factors. Here, we report the comprehensive clinicopathological and molecular analysis of an extra-gestational colorectal choriocarcinoma in a patient with probable Lynch syndrome. A 61-year-old female with history of gastric cancer at age 36 presented with a transmurally invasive tumor of the right hemicolon and liver metastasis. A right hemicolectomy was performed. Histopathological analysis showed a mixed trophoblastic and syncytiotrophoblastic differentiation, consistent with choriocarcinoma. Disease progression was rapid under oxaliplatin, capecitabine, irinotecan, and bevacizumab. Molecular phenotyping identified loss of mismatch-repair protein immunostaining for PMS2, microsatellite instability, a lack of MLH1 promoter methylation, and lack of BRAF mutation suggestive of Lynch syndrome. Targeted next-generation sequencing revealed an ataxia telangiectasia mutated (p.P604S) missense mutation. A bleomycin, etoposide, and cisplatin treatment protocol targeting germ cell neoplasia lead to disease remission and prolonged survival of 34 months. Comprehensive immunohistochemical and genetic testing is essential to identify uncommon cancers possibly related to Lynch syndrome. For rare tumors, personalized therapeutic approaches should take both molecular and morphological information into account.
27965933	0	26	Colorectal Choriocarcinoma	T038	UMLS:C0009402
27965933	54	68	Lynch Syndrome	T038	UMLS:C2931459
27965933	82	89	therapy	T058	UMLS:C0087111
27965933	93	110	colorectal cancer	T038	UMLS:C1527249
27965933	238	256	molecular analysis	T062	UMLS:C1513380
27965933	263	280	extra-gestational	T038	UMLS:C0032961
27965933	281	307	colorectal choriocarcinoma	T038	UMLS:C0009402
27965933	335	349	Lynch syndrome	T038	UMLS:C2931459
27965933	377	387	history of	T033	UMLS:C0262926
27965933	388	402	gastric cancer	T038	UMLS:C0024623
27965933	443	457	invasive tumor	T038	UMLS:C0677898
27965933	465	480	right hemicolon	T017	UMLS:C1305188
27965933	485	501	liver metastasis	T038	UMLS:C0494165
27965933	505	524	right hemicolectomy	T058	UMLS:C0192861
27965933	576	595	mixed trophoblastic	T038	UMLS:C0041182
27965933	600	621	syncytiotrophoblastic	T017	UMLS:C1135936
27965933	655	670	choriocarcinoma	T038	UMLS:C0008497
27965933	672	691	Disease progression	T038	UMLS:C0242656
27965933	708	719	oxaliplatin	T103	UMLS:C0069717
27965933	721	733	capecitabine	T103	UMLS:C0671970
27965933	735	745	irinotecan	T103	UMLS:C0123931
27965933	751	762	bevacizumab	T103	UMLS:C0796392
27965933	764	785	Molecular phenotyping	T058	UMLS:C1285572
27965933	805	828	mismatch-repair protein	T103	UMLS:C1333235
27965933	829	843	immunostaining	T058	UMLS:C0487602
27965933	848	852	PMS2	T103	UMLS:C1333235
27965933	854	880	microsatellite instability	T038	UMLS:C0920269
27965933	931	944	BRAF mutation	T038	UMLS:C1511021
27965933	959	973	Lynch syndrome	T038	UMLS:C2931459
27965933	1023	1062	ataxia telangiectasia mutated (p.P604S)	T103	UMLS:C3711796
27965933	1063	1080	missense mutation	T038	UMLS:C0599155
27965933	1084	1093	bleomycin	T103	UMLS:C0005740
27965933	1095	1104	etoposide	T103	UMLS:C0015133
27965933	1110	1119	cisplatin	T103	UMLS:C0008838
27965933	1120	1138	treatment protocol	T058	UMLS:C0040808
27965933	1149	1168	germ cell neoplasia	T038	UMLS:C4021985
27965933	1177	1194	disease remission	T033	UMLS:C0544452
27965933	1270	1285	genetic testing	T058	UMLS:C0393006
27965933	1311	1327	uncommon cancers	T038	UMLS:C4054123
27965933	1348	1362	Lynch syndrome	T038	UMLS:C2931459
27965933	1368	1379	rare tumors	T038	UMLS:C4054123
27965933	1394	1416	therapeutic approaches	T058	UMLS:C0087111